The success of combination antiretroviral therapy in the treatment of HIV-1-positive individuals has shifted clinical attention toward combination antiretroviral drug regimens that optimize tolerability, long-term safety, and durable efficacy. Wherever patients have access to treatment, morbidity and mortality are increasingly driven by non-HIV-associated comorbidities, which may be observed earlier than in age-matched controls and despite the best available combination antiretroviral therapy. Similarly, HIV-1-positive individuals are now diagnosed and treated earlier with anticipated lifelong therapy. The contribution of specific antiretroviral agents to long-term morbidity and mortality is dependent on the pharmacologic characteristics of these agents, and it is increasingly important in this context.
Keywords: Anti-Retroviral Agents; Attention; Clinical; Comorbidity; HIV; HIV Infections; HIV-1; Health Services Accessibility; Morbidity; Pharmacology; antiretroviral therapy; drug interactions; drug nephrotoxicity; pharmacokinetics.
Copyright © 2019 by the American Society of Nephrology.